SCHEMBL5541325

SCHEMBL5541325

FC(F)(F)Oc1ccccc1Nc1cc[c]cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 1/20 0.47
C1R P00736 1/20 0.43
AURKA O14965 1/20 0.43
P2RX7 Q99572 1/20 0.42
GAA P10253 1/20 0.42
ALDH1A1 P00352 1/20 0.39
MAPT P10636 1/20 0.39
MAPK1 P28482 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
DDB1 Q16531 1/20 0.38
CRBN Q96SW2 1/20 0.38
GBA1 P04062 1/20 0.37
SLC22A12 Q96S37 3/20 0.36
SLC40A1 Q9NP59 1/20 0.36
PTGES2 Q9H7Z7 1/20 0.36
CXCR2 P25025 1/20 0.36
RXFP1 Q9HBX9 1/20 0.35
P2RY1 P47900 1/20 0.34
IDH1 O75874 1/20 0.34
ALPL P05186 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5534664 0.87 MAPT (0.37) EPHX2C1RAURKAP2RX7GAA
SCHEMBL4376420 0.86 EPHX2 (0.51) EPHX2C1RAURKAP2RX7GAA
SCHEMBL3192934 0.82 EPHX2 (0.57) EPHX2C1RAURKAP2RX7GAA
SCHEMBL5541591 0.74 ALDH1A1 (0.48) EPHX2AURKAGAAALDH1A1MAPT
SCHEMBL9091194 0.73 EPHX2 (0.40) EPHX2C1RAURKAP2RX7GAA
SCHEMBL5535891 0.73 MAPT (0.50) EPHX2P2RX7GAAALDH1A1MAPT
SCHEMBL4057926 0.72 EPHX2 (0.49) EPHX2C1RAURKAP2RX7GAA
SCHEMBL5540028 0.72 KIF11 (0.49) EPHX2GAAALDH1A1MAPTSLC22A12
SCHEMBL5545445 0.72 SLC6A3 (0.40) P2RX7GAAALDH1A1MAPTL3MBTL1
SCHEMBL20043263 0.72 GAA (0.46) EPHX2C1RP2RX7GAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 EPHX2 3662/4885C1R 1202/4885AURKA 1846/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.